Menu
The goal of this activity is to provide a series of clinically meaningful expert insights in order to inform US-based practicing physicians about evolving clinical trials and data, emerging new treatments for DED, as well as the best practices for treating DED, managing and reducing the burden of these conditions, and improving patient outcomes.
(1/13) Welcome to our #tweetorial on Diagnosis, Novel Therapeutics, and Patient Perception in #DryEyeDisease. Follow this thread to learn more from our expert faculty, @DZEyeMD, a cornea, cataract, and refractive surgeon, on tips for better #EyelidHygiene compliance. pic.twitter.com/4am70pCiiS
— Springer IME (@SpringerIME) August 23, 2023
(1/25) Welcome to our #tweetorial on Diagnosis, Novel Therapeutics, and Patient Perception in #DryEyeDisease (#DED) Management.
— Springer IME (@SpringerIME) June 20, 2023
Follow this thread to learn more from one of our DED experts, Dr. Laura Periman @Dryeyemaster, a fellowship-trained cornea and refractive surgeon. pic.twitter.com/jPciKEgEfL
(1/15) Welcome to our #tweetorial on Diagnosis, Novel Therapeutics and Patient Perception in #DryEyeDisease Management. Follow this thread to learn more from our expert faculty, @LisaNijmMDJD, a cornea, cataract, and refractive surgeon, on diagnostic clinical pearls. pic.twitter.com/OswNxDFc69
— Springer IME (@SpringerIME) September 21, 2023
(1/13) Welcome to our #tweetorial on Diagnosis, Novel Therapeutics, and Patient Perception in #DryEyeDisease. Follow this thread to learn more from our expert faculty, @DZEyeMD, a cornea, cataract, and refractive surgeon, on tips for better #EyelidHygiene compliance. pic.twitter.com/4am70pCiiS
— Springer IME (@SpringerIME) August 23, 2023
(1/25) Welcome to our #tweetorial on Diagnosis, Novel Therapeutics, and Patient Perception in #DryEyeDisease (#DED) Management.
— Springer IME (@SpringerIME) June 20, 2023
Follow this thread to learn more from one of our DED experts, Dr. Laura Periman @Dryeyemaster, a fellowship-trained cornea and refractive surgeon. pic.twitter.com/jPciKEgEfL
(1/15) Welcome to our #tweetorial on Diagnosis, Novel Therapeutics and Patient Perception in #DryEyeDisease Management. Follow this thread to learn more from our expert faculty, @LisaNijmMDJD, a cornea, cataract, and refractive surgeon, on diagnostic clinical pearls. pic.twitter.com/OswNxDFc69
— Springer IME (@SpringerIME) September 21, 2023
In support of improving patient care, this activity has been planned and implemented by HMP Education and Springer Healthcare. HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
HMP Education designates this internet enduring activity for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In addition to the expert faculty, Springer Healthcare IME planners and staff include Jennifer Jett, Elizabeth Samander, and Alessandra Geffner-Smith. HMP Education planners and staff include Samantha Joy and Andrea Zimmerman, EdD.
No HMP Education or Springer Healthcare IME planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).
This activity is targeted to US-based primary care providers, ophthalmologists, ophthalmic nurses, pharmacists, and other HCPs involved in the care of patients with DED.
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within one hour; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™ you must complete the educational activity, complete the 6-question post-test and complete the activity evaluation form. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.
Periman Eye Institute, Seattle, WA
Laura Periman, MD is a board-certified ophthalmologist, fellowship-trained cornea and refractive surgeon and Ocular Surface Disease Expert. Dr Periman completed her Ophthalmology Residency as well as Cornea/Refractive Fellowship at the University of Washington in Seattle. She has written extensively on the topic of Ocular Surface Disease. She is an innovator and enthusiastic speaker who loves bridging the gap between basic science, clinical practice and patient compassion. As Director of Dry Eye Services and Clinical Research at her Periman Institute in Seattle, WA she combines her clinical care passion, scientific drive and innovative creativity to provide first class Ocular Surface Disease management.
Disclosures
Dr. Periman discloses the following relationships:
Consultant/ Speaker’s Bureau: Alcon, Aerie, Aldeyra, Allergan/Abbvie, Azura, Bausch & Lomb, Eyevance, Horizon, Kala, Lumenis, Mallinckrodt, Myze, Novartis, Nusight Ophthalmics, Olympic Ophthalmics, Quidel, Santen, Science Based Health, Scope, Sun, Tarsus, ThermaMEDx, Visant
Advisory Board: Alcon, Aldeyra, Allergan/Abbvie, Avellino, Azura, Bausch & Lomb, Bruder, Dompe, Eyedetec, Eyevance, Horizon, Kala, Lumenis, Myze, Novartis, Quidel, Santen, Science Based Health, Scope, Sun, Tarsus, ThermaMEDx, Versea, Visant
Research Grants: Alcon, Aerie, Kala, Lumenis, Mark Abelson MD, Novartis, Olympic Ophthalmics, Oyster Point Pharmaceuticals
Shareholder: Eyedtec, Myze, Quench Method
Eye Doctors of Washington, Washington DC
Dr. Fathy is a board-certified cataract, cornea, and refractive surgeon. Dr. Fathy earned her medical degree at the Vanderbilt University School of Medicine. She also completed a Master’s in Public Health with a concentration in Epidemiology while at Vanderbilt. She completed her ophthalmology residency at Wills Eye Hospital, where she served as an editor for The Wills Eye Manual. She further subspecialized in cornea and external disease as a fellow at the Wilmer Eye Institute at The Johns Hopkins Hospital.
She serves on the editorial board for the American Academy of Ophthalmology’s Young Ophthalmologists Info section. Dr. Fathy has been recognized by the American Medical Association with the Excellence in Medicine Award for her leadership and dedication to her patients and by the American Society of Cataract and Refractive Surgeons for her exemplary research and leadership in the field of ophthalmology.
Disclosures
Dr. Fathy discloses the following relationship:
Consultant: Zeiss
Medical Optometry America, Shrewsbury, PA
Medical Director of MOA-Shrewsbury, Leslie O’Dell, OD, FAAO, focuses on the management of ocular disease including glaucoma, dry eye, diabetic eye disease, and age-related macular degeneration. Dr. O’Dell graduated from Salus University (formerly Pennsylvania College of Optometry) and completed a residency at the Baltimore VA Hospital. Throughout her career, Dr. O’Dell has demonstrated her commitment to optimizing patient outcomes through her personalized approach to eye care. She is equally passionate about advancing the field of Optometry and leaving her mark through a wide variety of research endeavors aimed at improving the testing and treatment of ocular diseases.
Dr. O’Dell is a fellow in the American Academy of Optometry, a diplomate of the American Board of Optometry, and a member of the board of directors of the Optometric Glaucoma Foundation. She is a member of the Pennsylvania Optometric Association, Optometric Glaucoma Society, and Tear Film & Ocular Surface Society (TFOS). She is one of six TFOS Global Ambassadors for the United States. Dr. O’Dell is a founding member and current board member of the Intrepid Eye Society.
Disclosures
Dr. O’Dell discloses the following relationships:
Speaker: Allergan, Aeire, Sight Sciences, Sun Pharma, Kala Pharma
Consultant: Allergan, Bausch Health, Essiri Labs, JNJ vision, Kala Pharma, Novartis, Oyster Point, Sun Pharma, Sight Sciences, Tarsus
NVISION Eye Centers, Rowland Heights, CA
Dr. Zhu is a nationally acclaimed, board-certified ophthalmologist and fellowship-trained specialist in cornea, cataract, and laser refractive surgery. As a key opinion leader in laser vision correction and premium cataract surgery, Dr. Zhu serves as medical advisor to multiple ophthalmic companies and has published, lectured, and been featured in over 200 scientific journal articles, book chapters, national conferences, and press features. Dr. Zhu graduated top of her class from UCLA and received her M.D. from Harvard Medical School. She completed her residency at the prestigious Doheny Eye Institute/University of Southern California (USC) and completed her fellowship at Bascom Palmer Eye Institute, consistently ranked the #1 eye hospital by U.S. News and World Report.
Disclosures
Dr. Zhu discloses the following relationships:
Consultant: Alchemy Vision, Alcon, Allergan/Abbvie, Bausch & Lomb, Bruder, Bryn Mawr Communications, Entelexo, Eyesafe, Eyenovia, IrisVision, Johnson & Johnson, Lensar, Ocuphire, Sight Sciences, Tarsus Pharmaceuticals, Visus Therapeutics.
Speaker’s Bureau: Allergan/Abbvie, Santen
Research Grants: Alcon (2020-present), Lensar (2021-2022)
Shareholder: Glaukos
Warrenville EyeCare & LASIK, Warrenville, IL
Dr. Nijm is a board certified cornea, cataract and LASIK surgeon at Warrenville Eyecare & LASIK, licensed attorney, innovator and assistant professor at the University of Illinois Eye & Ear Infirmary. Dr. Nijm graduated from Benedictine University, and pursued a post-graduate education that uniquely combined her interests in patient care and health care policy advocacy. She received her dual MD/JD degree through Southern Illinois University School of Medicine and School of Law.
She leads Women in Ophthalmology as its CEO, has taught over 2500 ophthalmologists, and mentors physicians through MDNegotiation.com. Using her unique MD/JD dual degree, Dr. Nijm also advises leading medical device and pharmaceutical companies on new innovations. She most recently created www.RealWorldOphthalmology.com to serve as an educational resource to aid young ophthalmologists in successfully transitioning from training to practice.
Disclosures
Dr. Nijm discloses the following relationships:
Consultant/Advisor: Alcon Laboratories, Inc., Allergan, Inc., Azura Ophthalmics, Bausch + Lomb, Bruder Healthcare Company, Carl Zeiss Meditec, Dompe, Horizon Therapeutics Plc, Iveric Bio, Johnson & Johnson Vision, Novartis, Alcon Pharmaceuticals, Ocular Therapeutix, Oyster Point Pharma, Rayner Intraocular Lenses Ltd, Scope Health, Sun Ophthalmics, TruKera (TearLab) Corporation, THEA, Visus Therapeutics
Speaker’s Bureau: Allergan, Inc., Bausch + Lomb, Horizon Therapeutics Plc, Oyster Point Pharma, Sun Ophthalmics
Research Grants: Ocular Therapeutix
Shareholder: TruKera (TearLab) Corporation
